未知生产厂商
Fasinumab is a monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.
Fasinumab is a monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.
During embryonic development, nerve growth factor (NGF) binds to tropomyosin receptor kinase A receptor (TrkA) and the low-affinity p75 neurotrophin receptor (NTR) on developing neuronal cell surfaces, which activates signaling pathways involved in neuronal growth and survival. In adults, the primary role of NGF shifts towards influencing nociceptive signaling transduction by releasing inflammatory mediators and regulating ion channels or receptors. Fasinumab is a human IgG1k monoclonal antibody targeted against NGF, interrupting pain signaling pathways and thus alleviating pain and improving function in patients suffering from chronic pain conditions.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
